ARTICLE | Company News
Meda, Novartis sales and marketing update
May 16, 2011 7:00 AM UTC
Meda completed its previously announced acquisition of dermatology drug Elidel pimecrolimus from Novartis for $420 million in cash. The non-steroidal ascomycin derivative 1% cream is marketed to trea...